Phase 2 N=80 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=117 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Phase 3 N=28 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Responder Rate — 60.7; 63.6 percentage of responders
Phase 2 N=7 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
Phase 3 N=208 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Chronic Inflammatory Demyelinating Polyneuropathy · Polyradiculoneuropathy
Primary: Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period — 32.8; 38.6; 63.2 percentage of…
Phase 3 N=106 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
N/A N=15 Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Relapse of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms — 3; 12 Participants
Phase 2 N=34 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)
Phase 2 N=21 A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 10; 10 Participants
Phase 2 N=322 A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary: Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) — 66.5 percentage of participants
Phase 3 N=142 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Primary: Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score — .7971 proportion of subjects
Phase 3 N=132 A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Epoch 1: Relapse Rate — 31.4; 9.7 percentage of participants — p==0.0045
Phase 3 N=43 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Efficacy Endpoint: Responder Rate at End of Study — 32 Participants — p=<0.0001
Phase 3 N=82 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Number of Adverse Events (AEs) Per Infusion — 0.032 Adverse events per infusion
Phase 3 N=85 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality — 76; 20 Participants
Phase 3 N=44 Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
Multifocal Motor Neuropathy
Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms
Phase 2 N=60 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Myasthenia Gravis
Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
N/A N=26 Pregabalin in CIPN
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
Phase 2 N=128 Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221
Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=20 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Phase 2 N=2 Treatment of POEMS Syndrome With Daratumumab
POEMS Syndrome
Primary: Treatment Success — 0 Participants
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
N/A N=61 Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
Breast Cancer · Peripheral Neuropathy, Secondary to Drugs or Chemicals
Primary: Percentage of Participants With 'Pain' or 'no Pain' as Measured by the Numeric Pain Rating Scale — 30; 49; 70; 51 percentage of participants — p=0.053